Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80.

Article  CAS  PubMed  Google Scholar 

Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188–200.

CAS  PubMed  Google Scholar 

McCready VR. Radioiodine - the success story of nuclear medicine: 75th Anniversary of the first use of iodine-131 in humans. Eur J Nucl Med Mol Imaging. 2017;44:179–82.

Article  PubMed  Google Scholar 

Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102–18.

Article  CAS  PubMed  Google Scholar 

Lepareur N, Ramée B, Mougin-Degraef M, Bourgeois M. Clinical advances and perspectives in targeted radionuclide therapy. Pharmaceutics. 2023;15:1733.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–6.

Article  CAS  PubMed  Google Scholar 

Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018;91:20180136.

Article  PubMed  PubMed Central  Google Scholar 

Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:821–8.

Article  PubMed  Google Scholar 

Tumino D, Frasca F, Newbold K. Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2017;8:312.

Article  PubMed  PubMed Central  Google Scholar 

Nguyen NC, Anigati EM, Desai NB, Öz OK. Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary malignancies. Semin Nucl Med. 2024;54:488–96.

Article  PubMed  Google Scholar 

Wu W, Li S, Xu K, Meng Z. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study. Endokrynol Pol. 2023;74:260–70.

Article  CAS  PubMed  Google Scholar 

Hall P, Boice JD Jr, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1–4.

Article  CAS  PubMed  Google Scholar 

Seo GH, Cho YY, Chung JH, Kim SW. Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer: a nationwide, population-based study in Korea. Thyroid. 2015;25:927–34.

Article  PubMed  Google Scholar 

Kim S, Bang JI, Boo D, et al. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur J Nucl Med Mol Imaging. 2022;49:3547–56.

Article  CAS  PubMed  Google Scholar 

Su H, Yang F, Wang Z, et al. Meta-analysis of secondary hematologic malignancy risks following radioactive iodine therapy for differentiated thyroid cancer. Int J Surg. 2025;111:7312–21.

Article  PubMed  PubMed Central  Google Scholar 

Shim SR, Kitahara CM, Cha ES, Kim SJ, Bang YJ, Lee WJ. Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2125072.

Article  PubMed  PubMed Central  Google Scholar 

Pasqual E, Schonfeld S, Morton LM, et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J Clin Oncol. 2022;40:1439–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim J, Bae S, Choi J, et al. Association of high-dose radioactive iodine therapy with PPM1D-mutated clonal hematopoiesis in older individuals. Mol Oncol. 2025;19:3079–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furuya-Kanamori L, Bell KJ, Clark J, et al. Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis. J Clin Oncol. 2016;34:3672–9.

Article  PubMed  Google Scholar 

Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma—a systematic review. Cancer Treat Rev. 2015;41:925–34.

Article  CAS  Google Scholar 

Shank JB, Are C, Wenos CD. Thyroid cancer: global burden and trends. Indian J Surg Oncol. 2022;13:40–5.

Article  PubMed  Google Scholar 

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783–95.

Article  CAS  PubMed  Google Scholar 

Lamart S, Bouville A, Simon SL, et al. Comparison of internal dosimetry factors for three classes of adult computational phantoms with emphasis on 131I in the thyroid. Phys Med Biol. 2011;56:7317–38.

Article  PubMed  PubMed Central  Google Scholar 

Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841–985.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haddad RI, Bischoff L, Applewhite M, et al. NCCN guidelines insights: thyroid carcinoma, version 1.2025: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2025;23:e250033.

Avram AM, Giovanella L, Greenspan B, et al. SNMMI procedure standard/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med. 2022;63:15N-35N.

PubMed  Google Scholar 

Campennì A, Avram AM, Verburg FA, et al. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023;50:3324–48.

Article  PubMed  PubMed Central  Google Scholar 

Kim KJ, Song EY, Kim MJ, et al. 2025 Korean Thyroid Association management guidelines for radioactive iodine therapy in patients with hyperthyroidism. Endocrinol Metab (Seoul). 2025;40:342–56.

Article  PubMed  PubMed Central  Google Scholar 

Ali Hailan YM, Al-Dubai HN, Yassin MA. Chronic myeloid leukemia following exposure to radioactive iodine (I131): a systematic review. Oncology. 2023;101:362–8.

Article  CAS  PubMed  Google Scholar 

Frane N, Bitterman A. Radiation safety and protection. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK557499/. Accessed 18 Jan 2026.

Sohn SY, Choi JY, Jang HW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid. 2013;23:741–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kessler L, Palla J, Baru JS, et al. Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr Pract. 2014;20:737–45.

Article  PubMed  Google Scholar 

Azizi F, Amouzegar A, Tohidi M, et al. Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid. 2019;29:1192–200.

Article  CAS  PubMed  Google Scholar 

Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin. 1998;37:23–5.

Article